| Cutaneous Mature B-Cell Neoplasm studied in …STUDIED_INderived65 of 65show fewer |
|---|
| → studied in | NCT05821088Phase 2 · active not recruiting Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 65 trials mapped (10 active) | — | — | Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07705386active not recruiting Development of an AI-Assisted Diagnostic Tool for Mycosis Fungoides and Other Cutaneous Lymphoproliferative Diseases Using Microscopic Image Analysis: A Training and Validation Study · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04799275Phase 2/Phase 3 · active not recruiting Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 65 trials mapped (10 active) | — | — | Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01815749Phase 1 · active not recruiting Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03038672Phase 2 · active not recruiting Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas · condition mapped CURATED_BROADER · 65 trials mapped (10 active) | — | — | Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05507541Phase 2 · active not recruiting TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 65 trials mapped (10 active) | — | — | Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02213913Phase 1/Phase 2 · completed Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05544019Phase 1 · recruiting Study of SGR-1505 in Mature B-Cell Neoplasms · condition mapped ONTOLOGY_EXACT · 65 trials mapped (10 active) | — | — | Primary Cutaneous Follicle Center Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01199562active not recruiting Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06834373Phase 2 · recruiting Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy · condition mapped CURATED_BROADER · 65 trials mapped (10 active) | — | — | Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05202782Phase 2 · active not recruiting Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 65 trials mapped (10 active) | — | — | Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01769222Phase 1 · terminated Ipilimumab and Local Radiation for Selected Solid Tumors · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01523223Phase 1 · completed Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01000753completed Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05414162unknown Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01805037Phase 1/Phase 2 · terminated Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02037256NA · completed Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01678443Phase 1 · terminated Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01258998Phase 2 · completed Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00089011Phase 2 · completed Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00006251Phase 1/Phase 2 · completed Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00014235NA · completed Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01239875early Phase 1 · completed Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00003196NA · completed Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01326702Phase 1/Phase 2 · completed Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01839916Phase 2 · completed Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01408043NA · terminated Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01093586Phase 2 · completed Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01273766Phase 2 · completed Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01789255Phase 2 · completed Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01053494NA · completed Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02168907Phase 1 · terminated CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01129193Phase 1 · completed AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01567709Phase 1 · completed Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00867529Phase 2 · completed Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01254578Phase 1 · completed Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers · condition mapped ONTOLOGY_EXACT · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00073918Phase 2 · completed Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01419795Phase 2 · terminated Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00072514Phase 2 · completed Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00118352Phase 2 · completed Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00601718Phase 1/Phase 2 · completed Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00112593NA · completed Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01110135Phase 2 · completed Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00244855Phase 2 · completed Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01427881Phase 2 · completed Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00049504Phase 2 · completed Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01652014Phase 2 · withdrawn Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01748721Phase 1 · completed MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01045928Phase 1 · terminated Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02109224Phase 1 · terminated Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01658319Phase 1 · completed Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01959477early Phase 1 · completed Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00608361Phase 1 · completed Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00720135Phase 1 · completed Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01769911NA · withdrawn Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01158274Phase 1 · completed RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00089076Phase 1/Phase 2 · terminated MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00054639Phase 2 · completed Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00933985Phase 1 · terminated Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00890747Phase 1 · completed Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00499811Phase 1 · completed Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00458731Phase 1 · completed Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00769288Phase 1 · completed FAU in Treating Patients With Advanced Solid Tumors or Lymphoma · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01116154Phase 1 · terminated Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01177371Phase 2 · completed High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma · condition mapped ALIAS · 65 trials mapped (10 active) | — | — | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |